Preview:
DESCRIPTION
Citation preview
- 1.
- M.V. Lomonosov Moscow State University Faculty of Basic
Medicine
- 2.
- Lung cancer is the commonest malignancy and leading cause of
cancer deaths.
- At the moment , the development of Non Small Cell Lung Cancer
(NSCLC) in 25 30% of cases is diagnosed the local-extended process
and in 40 50% distant metastasis are revealed.
- The conservative methods of treatment occupy key place.
- 3.
- The 5-year relative survival rate varies markedly depending on
the stage at diagnosis, from 49% to 16% to 2% for patients with
local, regional, and distant stage disease respectively.
- If high mitotic rate and tumor necrosis associated with poor
prognosis.
- 4. Published Chemotherapy Regimens Schedule 1 Cisplaitn 50 mg/m
2 days 1 and 8 Vinorelbine 25 mg/m 2 days 1, 8, 15, 22 Every 28
days for 4 cycles 2 Cisplaitn 100 mg/m 2 on day 1 Vinorelbine 30
mg/m 2 days 1, 8, 15, 22 Every 28 days for 4 cycles 3 Cisplaitn
75-80 mg/m 2 on day 1 Vinorelbine 25-30 mg/m 2 days 1, 8 Every 28
days for 4 cycles 4 Cisplaitn 100 mg/m 2 on day 1 Etoposide 100
mg/m 2 day 1-3 Every 28 days for 4 cycles 5 Cisplaitn 80 mg/m 2 day
1 Vinblastine 4 mg/m 2 days 1, 8, 15, 22 Every 28 days for 4 cycles
Acceptable Cisplaitn-base Regimens 1 Cisplatin 80 mg/m 2 on day 1
Gemcitabine 1000 mg/m 2 on days 1, 8 Every 21 days 2 Cisplatin 80
mg/m 2 Docetaxel 75 mg/m 2 Every 21 days Chemotherapy Regimens for
patients with comorbidities or patients not able to tolerate
cisplatin 1 Paclitaxel 200 mg/m 2 on day 1 Carboplatin AUC 6 on day
1 Every 21 days
- 5.
- EGFR is expressed in 40 - 80% of lung cancers.
- Gefitinib (Iressa 250 mg) and erlotinib (Tarseva 150 mg) were
the first two agents to target the tyrosine kinase of the EGFR.
Both of these agents have activity in NSCLC.
- On the 1 st July 2009 the European Commission granted marketing
authorisation for IRESSA for the treatment of adults with locally
advanced or metastatic NSCLC.
- The National Institute for Clinical Excellence (NICE) has
approved Tarceva as an alternative treatment to the chemotherapy
drug docetaxel for people with non-small cell lung cancer.
- Bevacizumab, to improve survival when combined with
chemotherapy in the first-line setting.
- In currently aflibercept with the combination of other drugs is
in phase III cliinical trails.
- 6.
- To determine the significant effects of different chemotherpy
regimes
- 7.
- To identify which one is more effective than other chemotherapy
regimes
- To determine the toxicities of the drugs
- 8.
- - 95 patients with nom small cell lung cancer stage III IV
(Blokhins Russian Cancer Research Center from 2007 to march 2008)
ECOG performance status